GTx, Inc. (NASDAQ:GTXI) has received an average broker rating score of 3.00 (Hold) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating. GTX’s rating score has declined by 200% in the last three months as a result of various analysts’ ratings changes.
Brokerages have set a 12-month consensus target price of $1.75 for the company and are predicting that the company will post ($0.22) EPS for the current quarter, according to Zacks. Zacks has also given GTX an industry rank of 82 out of 257 based on the ratings given to its competitors.
A number of brokerages recently issued reports on GTXI. Zacks Investment Research cut shares of GTX from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine cut shares of GTX from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Stifel Nicolaus cut shares of GTX from a “buy” rating to a “hold” rating in a report on Friday, September 21st. Robert W. Baird cut shares of GTX from an “outperform” rating to a “neutral” rating and set a $17.00 target price for the company. in a report on Friday, September 21st. Finally, BidaskClub cut shares of GTX from a “buy” rating to a “hold” rating in a report on Thursday, September 20th.
NASDAQ:GTXI opened at $1.49 on Friday. GTX has a 12 month low of $1.32 and a 12 month high of $25.60. The stock has a market capitalization of $35.84 million, a PE ratio of -0.85 and a beta of 1.60.
GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). As a group, research analysts predict that GTX will post -1.65 earnings per share for the current year.
GTX Company Profile
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Featured Article: What is the Ex-Dividend Date in Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.